(IN BRIEF) CVC Capital Partners has agreed to sell a 37% minority stake in Syntegon to Apollo-managed funds while retaining majority ownership, marking the start of a new growth phase for the company. Since CVC’s investment, Syntegon has achieved strong … Read the full press release
Posted in Business, Food & Beverage, Industrial, Infrastructure & Utilities, Insurance, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Apollo, biotechnology, Can Toygar, CVC and Apollo partnership strengthens Syntegon’s expansion plans and leadership in pharma biotech and food technology markets, CVC Capital Partners, food industry, Global Growth, industrial technology, INNOVATION, investment, Jeremy Honeth, Klenzaids, manufacturing systems, Marc Strobel, Minority Stake, North America expansion, pharma industry, private equity, Stuttgart, Syntegon, Telstar, Torsten Türling
(IN BRIEF) Sanofi has received Breakthrough Therapy designation from the US FDA for venglustat, an investigational oral drug targeting neurological symptoms of type 3 Gaucher disease, a rare genetic disorder with no approved treatments for its neurological manifestations. The designation … Read the full press release
Posted in European Union, France, Healthcare, Marketing, Pharma & Biotech
Tagged biotechnology, clinical trials, enzyme replacement therapy, Fast Track Designation, FDA, Gaucher disease type 3, GD3, imiglucerase, Karin Knobe, LEAP2MONO, lysosomal storage disorder, orphan drug, rare disease, Sanofi, Sanofi Strengthens Pipeline with Venglustat Following FDA Breakthrough Designation for Rare Neurological Disorder, US Food and Drug Administration, venglustat
(IN BRIEF) Researchers at the Technical University of Munich have developed a new drug candidate that significantly enhances the effectiveness of the antibiotic metronidazole against Helicobacter pylori, a bacterium linked to stomach cancer. By introducing targeted chemical modifications, the team … Read the full press release
Posted in Chemicals, Education, Germany, Healthcare, Industrial, Management, Pharma & Biotech, Science, Technology
Tagged antibiotic resistance, biotechnology, drug development, Helicobacter pylori, Marianne Pandler, Markus Gerhard, metronidazole, Michael Groll, Michaela Fiedler, microbiome, Nature Microbiology, Oxidative stress, Stephan A. Sieber, stomach cancer, Technical University of Munich, TUM, TUM Researchers Achieve Breakthrough in Antibiotic Enhancement with New Compound Showing Strong Activity Against Resistant Bacteria
(IN BRIEF) The European Investment Bank has launched its first pre-IPO advisory agreement, partnering with Swedish biotechnology company Anocca to support its preparation for a potential future stock-market listing. Delivered through the InvestEU Advisory Hub, the initiative focuses on strengthening … Read the full press release
Posted in Banks, European Union, Financial, Healthcare, Industrial, Infrastructure & Utilities, Investment, Luxembourg, News, Pharma & Biotech, Sweden
Tagged Anocca, biotechnology, cancer treatment, capital markets, Capital Markets Union, EIB, EIB Expands Support for European Growth Companies with New Pre IPO Advisory Initiative Focused on Capital Market Readiness, European growth companies, European Investment Bank, InvestEU Advisory Hub, IPO readiness, Jacob Michlewicz, Karl Nehammer, pre IPO advisory, T cell immunotherapy, venture debt
A new citizen-science project is investigating a possible universal structural pattern in protein 3D architecture The pattern involves amino acids clustering by chemical type into mosaic-like arrangements Findings are based on analysis of over 160,000 protein structures and computational simulations … Read the full press release
Posted in European Union, Healthcare, Pharma & Biotech, Science, Spain, Technology
Tagged 3D protein structure, 3D protein-structure snapshots, 3D structure of proteins, a citizen-science project, amino acid clustering, amino acids, Bioinformatics, biology, biomolecules, biotechnology, citizen science, citizen-science platforms, collaborative science, computational biology, crowdsourced research, data analysis, drug discovery, EU-Citizen Science, European Commission, Francisco Javier Lobo Cabrera, global citizen-science initiative, Horizon 2020, Horizon 2020 programme, image repository, Jmol, Jmol software, José Antonio Prado-Bassas, María Ángeles García-Rosado Delgado, molecular visualization, Mosaic Q pattern, novel 3D protein structural pattern, Pablo de Olavide University, protein 3D structure, protein architecture, protein data analysis, protein research, protein structure, proteins, Proteins Mosaic Q, scientific crowdsourcing, SciStarter, stochastic simulations, structural biology, structural patterns in proteins, University of Seville
(IN BRIEF) Technical University of Munich researchers have found a way to boost oxidase biosensor accuracy from about 50% to 99% by using an alcohol oxidase oxygen scavenger that prevents signal loss, eliminating the need for calibration. The advancement enhances … Read the full press release
Posted in Agriculture, Education, Germany, Healthcare, Management, Pharma & Biotech, Science, Technology
Tagged agriculture nitrogen test, AI health data, AI-Data, alcohol oxidase, and Crop Analysis, biosensor accuracy, biotechnology, Breakthrough at TUM Boosts Oxidase Sensor Performance for Health, creatinine, glucose monitoring, Horizon Europe, Huijie Zhang, lactate, LiveSen-MAP, Mohamed Saadeldin, Nicolas Plumeré, oxidase biosensors, oxygen scavenger, personalised medicine, Science Advances, sustainability, Technical University of Munich, TUM, wearable diagnostics
(IN BRIEF) The European Investment Bank and Angelini Ventures have signed a €150 million funding agreement to support early- and growth-stage European startups in biotechnology, medical technology, and digital health. Each partner will invest €75 million over six years in … Read the full press release
Posted in Banks, European Union, Financial, Healthcare, Infrastructure & Utilities, Investment, Italy, Luxembourg, News, Small Business
Tagged ADCs, Adcytherix, Angelini Industries, Angelini Ventures, antibody-drug conjugates, biotechnology, corporate venture capital, deeptech, digital health, EIB, EIB Partners with Angelini Ventures to Back High-Impact Healthcare Startups and Boost Europe’s Technological Competitiveness, EU competitiveness, European Innovation, European venture capital, Gelsomina Vigliotti, life sciences, medtech, Paolo Di Giorgio, scale-up, Sergio Marullo di Condojanni, startup financing, TechEU, €150 million investment
(IN BRIEF) The German Research Center for Artificial Intelligence (DFKI) and Mainz University Medical Center have initiated the MARK project to understand and predict the biological aging of the immune system using artificial intelligence. Funded by the Rhineland-Palatinate Ministry of … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Environment, Germany, Healthcare, News, Pharma & Biotech, Science, Society, Technology
Tagged aging research, AI in medicine, Andreas Dengel, artificial intelligence, biotechnology, blood stem cells, Center for Thrombosis and Hemostasis, Clemens Hoch, data science, DFKI, DFKI and Mainz researchers pioneer AI-driven insights into immune decline and age-related health risks, Germany, healthy aging, immune system aging, Kaiserslautern, life sciences, Mainz, Mainz University Medical Center, MARK project, MARK project combines artificial intelligence and biotechnology to advance healthy aging research in Rhineland-Palatinate, Molecular Analysis of Age-Related Risk Mechanisms, predictive health models, Rhineland-Palatinate Ministry of Science and Health, Wolfram Ruf
(IN BRIEF) Boehringer Ingelheim and CDR-Life have expanded their partnership through a global licensing agreement to develop CDR111, a trispecific M-gager® antibody designed to reset the immune system by selectively targeting B cells. The collaboration builds upon their prior success … Read the full press release
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged antibody-based therapy, Arthritis, autoimmune diseases, B cells, biotechnology, Boehringer Ingelheim, Boehringer Ingelheim and CDR-Life Expand Partnership with New Global Licensing Deal to Advance Autoimmune Disease Therapies, Carine Boustany, CDR-Life, CDR111, Christian Leisner, Geographic Atrophy, global licensing agreement, immune system reset, lupus, multiple sclerosis, pharmaceutical collaboration, T-cell engager, trispecific M-gager, USD 570 million deal, VERDANT Phase 2 trial
(IN BRIEF) The European Investment Bank (EIB) has provided a €20 million loan to Overture Life to develop automated and AI-driven technologies for in vitro fertilization (IVF) and egg freezing. The funding supports the company’s R&D, production expansion, and clinical … Read the full press release
Posted in Artificial Intelligence (AI), Banks, European Union, Financial, Healthcare, Investment, Luxembourg, News, Pharma & Biotech, Science, Spain, Technology
Tagged AI in healthcare, Bio-Europe 2025, biotechnology, DaVitri platform, EIB, EIB Backs Overture Life’s Innovation to Make IVF More Efficient and Widely Available through AI, EIB Invests €20 Million in Overture Life to Advance AI-Based Fertility and IVF Technologies, European Innovation, European Investment Bank, fertility preservation, fertility technology, Hans Gangeskar, healthcare digitalisation, innovation funding, InvestEU, IVF automation, Karl Nehammer, life sciences, Overture Life, reproductive health, TechEU, Vienna, Women’s Health
(IN BRIEF) Boehringer Ingelheim has licensed a pre-clinical small molecule program from Kyowa Kirin to develop a potential first-in-class therapy for autoimmune diseases, a major global health challenge affecting around 10% of the population. The deal grants Boehringer exclusive worldwide … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged autoimmune diseases, biotechnology, Boehringer Ingelheim, Boehringer Ingelheim Secures Exclusive Global Rights to Develop New Autoimmune Treatment from Kyowa Kirin, Boehringer Ingelheim Strengthens Autoimmune Disease Pipeline with Licensing Agreement from Kyowa Kirin, Carine Boustany, chronic inflammation, drug development, global health, immunology, inflammatory diseases, Kyowa Kirin, licensing agreement, pharmaceutical innovation, pre-clinical program, respiratory diseases, small molecule therapy, Takeyoshi Yamashita
(IN BRIEF) Causeway Therapeutics, a University of Glasgow spin-out, has announced strong Phase 2 results for its novel microRNA therapy, TenoMiR®, used to treat tennis elbow. The study, involving 123 patients across the UK and USA, showed significant improvements in … Read the full press release
Posted in Education, Healthcare, Industrial, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biotechnology, Causeway Therapeutics, Causeway Therapeutics Advances TenoMiR® Development Following Strong Phase 2 Results, clinical research, Declan Doogan, Derek Gilchrist, Glasgow City Council, Glasgow Riverside Innovation District, Iain McInnes, lateral epicondylitis, microRNA therapy, miR29a, Neal Millar, orthopaedic innovation, phase 2 trial, Phase 3 development, Promising Clinical Data Propel Glasgow Biotech Causeway Therapeutics Toward Full Development of TenoMiR®, Scott Rodeo, Scottish Enterprise, tendinopathy, tendon regeneration, tennis elbow, TenoMiR, University of Glasgow
Pertussis cases surge: Over 60,000 reported in Europe; infants most at risk. Maternal vaccination expands: Finland, Norway, and UK updated pregnancy vaccine strategies. BioNet advances: Submitted recombinant pertussis vaccine to EMA; secured EU-GMP approval. Nasal vaccine progresses: ILiAD’s BPZE1 granted … Read the full press release
Posted in Denmark, European Union, Finland, France, Germany, Healthcare, Ireland, News, Norway, Pharma & Biotech, Science, United Kingdom
Tagged acellular pertussis vaccine, Adacel, antibody avidity, antigen dose, ASEAN, Bio Farma, BioNet, biotechnology, booster dose, Boostrix-IPV, BPZE1, certification, Chulalongkorn University, clinical trial, compliance, Dario Cresci, dTap, ECDC, EMA, EU-GMP, EU-GMP certification, EU/EEA, Europe Confronts Pertussis Resurgence as Infant Cases Rise Amid Falling Immunity and Vaccination Gaps, Europe Faces Pertussis Resurgence Amid Waning Immunity and Falling Maternal Vaccination Rates, European Medicines Agency, European Union, European Union Good Manufacturing Practice, Europe’s Pertussis Vaccine Market Opens to New Entrants as Demand Rises, From EU-GMP Certification to ASEAN Partnerships BioNet Broadens Its Global Vaccine Strategy, GMP production facilities, GSK, Hanna Nohynek, health policy, HPRA, human challenge trial, hVIVO, ILiAD Biotechnologies, immunization strategy, infant protection, Innovation Passport, Institut Pasteur, intranasal vaccine, Ireland Health Products Regulatory Authority, Lancet Infectious Diseases, maternal vaccination, MHRA, mucosal immunity, outbreak, pandemic recovery, Pertagen®, pertussis, pertussis vaccine, Pertussis Vaccine Manufacturing, pharmaceutical quality, Phase 3, Philippe Guillot-Chêne, pregnancy immunization, public health, recombinant pertussis vaccine, recombinant pertussis vaccines, regulatory approval, Sanofi, Tdap, TdaP combination vaccine, V, vaccine, vaccine blunting, vaccine development, Vaccine Hesitancy, vaccine pipeline, vaccine rollout, vaccine shortage, vaccine supply, vaccine uptake, VacPertagen, whooping cough
(IN BRIEF) Brenntag has signed an exclusive European distribution agreement with ArcticZymes AS for its line of salt-active nucleases—SAN HQ, SAN-HQ GMP, M-SAN HQ, and M-SAN HQ GMP—used in gene therapy, vaccine manufacturing, and bioprocessing. Signed during the CPHI fair … Read the full press release
Posted in Business, Chemicals, Financial, Germany, Industrial, Management, Pharma & Biotech
Tagged ArcticZymes, biopharma, biopharmaceutical innovation, bioprocessing, biotechnology, Brenntag, Brenntag and ArcticZymes Join Forces to Support Growth in Biopharmaceutical and Gene Therapy Markets, CPHI Frankfurt, downstream processing, enzyme distribution, enzymes, European partnership, gene therapy, GMP, Joakim Rehné, life sciences, M-SAN HQ, nucleases, Paul Blackburn, SAN HQ, vaccine manufacturing
BioNet earns EU-GMP certification for its acellular pertussis vaccine, confirming compliance with EU manufacturing and quality standards. Inspection by Ireland’s HPRA supports EMA review of BioNet’s recombinant vaccine candidate VacPertagen. Partnerships expanding: MoU with Indonesia’s Bio Farma to accelerate TdaP … Read the full press release
Posted in European Union, France, Healthcare, Ireland, Pharma & Biotech, Science
Tagged acellular pertussis vaccine, BioNet, BioNet’s EU-GMP Certification Marks Strategic Step Toward EMA Review and Expands Global Vaccine Reach, BioNet’s Manufacturing Accreditation Aligns with Growing International Efforts to Reinforce Pertussis Vaccine Supply, biotechnology, certification, compliance, Dario Cresci, EMA, EU-GMP certification, European Medicines Agency, European Union, European Union Good Manufacturing Practice, From EU-GMP Certification to ASEAN Partnerships BioNet Broadens Its Global Vaccine Strategy, GMP production facilities, HPRA, Ireland Health Products Regulatory Authority, Pertagen®, pertussis, pertussis vaccine, Pertussis Vaccine Manufacturing, pharmaceutical quality, Philippe Guillot-Chêne, recombinant pertussis vaccines, Regulatory Milestone and Research Progress Signal BioNet’s Expanding Role in Next-Generation Vaccine Development, V, vaccine, VacPertagen
(IN BRIEF) BioNet has achieved European Union Good Manufacturing Practice (EU-GMP) certification, a key international standard that validates its facilities and processes for producing high-quality pharmaceuticals. This certification, granted after inspection by Ireland’s Health Products Regulatory Authority (HPRA), allows BioNet … Read the full press release
Posted in European Union, France, Healthcare, Ireland, Pharma & Biotech
Tagged acellular pertussis vaccine, BioNet, biotechnology, certification, compliance, Dario Cresci, EMA, EU-GMP certification, European Medicines Agency, European Union, European Union Good Manufacturing Practice, GMP production facilities, HPRA, Ireland Health Products Regulatory Authority, Pertagen®, pertussis, pertussis vaccine, Pertussis Vaccine Manufacturing, pharmaceutical quality, Philippe Guillot-Chêne, recombinant pertussis vaccines, vaccine, VacPertagen
(IN BRIEF) Novartis announced a definitive agreement to acquire Avidity Biosciences for USD 12 billion in cash, in a move that strengthens its neuroscience franchise and accelerates its xRNA therapeutic strategy. The acquisition brings Avidity’s late-stage programs in myotonic dystrophy … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged acquisition, Antibody Oligonucleotide Conjugates, AOCs, Avidity Biosciences, Basel, biopharma, biopharmaceutical innovation, biotechnology, clinical research, DM1, DMD, drug development, Duchenne muscular dystrophy, EXPLORE44 trial, facioscapulohumeral muscular dystrophy, FORTITUDE trial, FSHD, genetic medicine, HARBOR trial, muscle-directed therapy, myotonic dystrophy type 1, neuromuscular diseases, Novartis, Novartis Strengthens Neuroscience Franchise with Acquisition of Avidity Biosciences and Its Muscle-Directed RNA Platform, RNA delivery, RNA therapeutics, San Diego, SpinCo, Vas Narasimhan, xRNA strategy
(IN BRIEF) Evotec SE announced it has received a US$ 25 million payment from Bristol Myers Squibb, marking progress in their joint neuroscience partnership focused on neurodegenerative diseases. The milestone payment will further advance the companies’ preclinical pipeline and research … Read the full press release
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Technology
Tagged biotechnology, BMS-986419, Bristol-Myers Squibb, clinical trials, Cord Dohrmann, disease-modifying therapies, drug discovery, Evotec and Bristol Myers Squibb Advance Neuroscience Collaboration with New Funding Milestone, Evotec SE, EVT8683, milestone payment, neurodegenerative diseases, neuroscience, neuroscience collaboration, neuroscience research, pharmaceutical innovation, preclinical research, strategic partnership, translational medicine
(IN BRIEF) Symrise has made a strategic equity investment in U.S.-based biotech firm Cellibre to drive innovation in sustainable biomanufacturing. The collaboration will accelerate the commercialization of natural flavor ingredients and cosmetic bioactives produced through precision fermentation. By combining Symrise’s … Read the full press release
Posted in Apparel, Fashion & Beauty, Chemicals, Food & Beverage, Germany, Marketing, Pharma & Biotech
Tagged Ben Chiarelli, biomanufacturing, biotechnology, biotechnology investment, Cellibre, Clean Beauty, corporate sustainability, cosmetic bioactives, environmental responsibility, fermentation-derived ingredients, food and beverage industry, global supply chain, Imke Meyer, natural flavors, nutraceuticals, Precision Fermentation, sustainable cosmetics, Sustainable Ingredients, sustainable innovation, Symrise, Symrise Partners with Cellibre to Accelerate Biotechnology Innovation in Natural Flavors and Cosmetic Actives, taste balancing
(IN BRIEF) Sanofi’s investigational therapy efdoralprin alfa met all primary and key secondary endpoints in the Phase 2 ElevAATe study for alpha-1 antitrypsin deficiency emphysema, demonstrating superior efficacy compared to standard plasma-derived therapy. The results highlight its potential as the … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged AATD emphysema, alpha-1 antitrypsin deficiency, biotechnology, Christopher Corsico, clinical research, David Geffen School of Medicine, efdoralprin alfa, ElevAATe OLE, ElevAATe study, FDA Fast Track, functional AAT, Igor Barjaktarevic, orphan drug designation, phase 2 trial, protein replacement therapy, pulmonary medicine, rare disease, recombinant therapy, respiratory health, respiratory innovation, Sanofi, Sanofi’s Efdoralprin Alfa Shows Superior Results in Phase 2 AATD Emphysema Trial, SAR447537, UCLA
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?